NBIX

152.9432.33%
WH

William H. Rastetter

Independent Chairman of the Board

Dr. William H. Rastetter, also known as Bill, Ph.D., is Independent Board Member at Iambic Therapeutics, Inc. since March 2023 and serves as its Chairperson. He has been the Chairman of the Board at Daré Bioscience, Inc. since July 11, 2019. Dr. Rastetter served as the Chairman of GRAIL, Inc. from November 2017 to November 2018 and served as Director of GRAIL, Inc. since January 2016. He serves as an Advisor to Illumina Ventures. Dr. Rastetter co-Founded Receptos, Inc in 2009 and served as its Executive Chairman from May 2009 to August 27, 2015. He served as an Interim Chief Executive Officer of Receptos, Inc from May 2009 to December 2, 2010. He served as a Director of Receptos, Inc from May 2009 to August 27, 2015. From 2006 to February 2013, Dr. Rastetter served as a partner in the venture capital firm of Venrock Associates from 2006 to 2013. Dr. Rastetter served as a Partner at VR Adviser, LLC from 2006 to February 2013. He co-founded Receptos, Inc. and served as its Chairman until it was sold to Celgene Corporation in 2015. Dr. Rastetter was the Chief Executive Officer of Idec Pharmaceuticals, Incorporated from 1986 to 2003. Upon the merger of Idec Pharmaceuticals and Biogen, Incorporated in 2003, Dr. Rastetter served as Chairman of Biogen Idec until the end of 2005. He focused on biotechnology investments. He served as the President and Chief Executive Officer of Biogen Idec Inc from December 1986 to January 2002, the Chief Executive Officer from January 2002 to November 2003 and served as an Executive Chairman. Dr. Rastetter served as the President at IDEC Pharmaceuticals Corp. from 1986 to 2002. Dr. Rastetter served as the Chief Financial Officer at IDEC Pharmaceuticals Corp. from December 1986 to November 2003, Chief Executive Officer from December 1986 through November 2003, the Chairman from May 1996 to November 2003 and a Director of IDEC Pharmaceuticals Corp. since 1986. From 1984 to 1986, he served as a Director of Corporate Ventures at Genentech Inc and served in a scientific capacity at Genentech. He has been the Chairman of Fate Therapeutics, Inc. since November 2011. Dr. Rastetter was an Interim Chief Executive Officer at Fate Therapeutics, Inc since February 2012 until October 15, 2012. He joined Fate Therapeutics on December 14, 2011. Dr. Rastetter has been the Chairman of the Board of Neurocrine Biosciences Inc. since May 25, 2011 and has been a Director since February 8, 2010. He had been Independent Director of Regulus Therapeutics Inc. since April 1, 2013 until June 25, 2025. He serves on the Board of Trustees for Caltech. Dr. Rastetter served on the board of directors of Cerulean Pharma Inc., a publicly held biotechnology company since January 2014, as its lead independent director from April 2014 to June 2016 and as its chairman from June 2016 until July 2017 when Cerulean and Daré Bioscience Inc. completed a reverse merger and he serves as chairman of the board of the surviving company, Daré Bioscience Inc., a publicly-traded company. He has been a Director of Daré Bioscience, Inc. since January 2014. He also serves as a strategic advisor to Leerink Partners. Dr. Rastetter has been Life Director at BIOCOM, Inc since April 2007. He is a Board Member of the California Healthcare Institute. He served as the Non-Executive Chairman of Illumina Inc. from January 2005 to January 28, 2016 and has been a Director of Illumina Inc. from November 1998 to January 28, 2016. He served as Executive Chairman of Biogen Idec Inc from November 2003 to December 30, 2005 and a Director from 1986 to December 30, 2005. He served as a Director of Argonaut Technologies Inc. since February 8, 2010. He served as a Director of Spiros Development Corp., since 1998. Dr. Rastetter served as a Director of the Biocatalysis group and a Director of Chemical Sciences. he served as a Director of Spiros Development Corporation II Inc. Dr. Rastetter served on the Boards of Directors of Genentech's joint venture companies, Genencor (with Corning and A.E. Staley), HP Genenchem (with Hewlett Packard), GLC Associates (with Lubrizol Corp.) and Travenol-Genentech Diagnostics (with Travenol Laboratories). From 1975 to 1982, Dr. Rastetter held various faculty positions at the Massachusetts Institute of Technology. He held various faculty positions at MIT, won the award for Excellence in the Teaching of Chemistry at Harvard and is an Alfred P. Sloan Fellow. Dr. Rastetter is an R. B. Woodward Visiting Scholar of the Department of Chemistry and Chemical Biology at Harvard University. Dr. Rastetter is co-founder and Chairman of the non-profit, San Diego Squared, that focuses on preparing students from underserved communities for careers in STEM. He is the author of numerous scientific papers and patent applications in the fields of organic and bio-organic chemistry, protein and enzyme engineering and biotechnology. Dr. Rastetter holds a Ph.D. Degree and an M.A. degree in Chemistry from Harvard University and an S.B. in Chemistry, Phi Beta Kappa and Phi Lambda Upsilon, from Massachusetts Institute of Technology. Currently, he serves as the Chairman of the Board of Directors for Fate Therapeutics, a publicly traded company focused on cellular therapie.

Positions